Sionna Therapeutics (NASDAQ:SION – Get Free Report) announced its earnings results on Thursday. The company reported ($3.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.68) by ($0.70), Zacks reports.
Sionna Therapeutics Stock Performance
Shares of Sionna Therapeutics stock opened at $13.88 on Thursday. Sionna Therapeutics has a 1 year low of $13.20 and a 1 year high of $25.19.
Analysts Set New Price Targets
Several analysts have recently weighed in on the stock. Stifel Nicolaus assumed coverage on shares of Sionna Therapeutics in a report on Tuesday, March 4th. They set a “buy” rating and a $32.00 price objective for the company. TD Cowen initiated coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a “buy” rating on the stock. Finally, Guggenheim started coverage on Sionna Therapeutics in a report on Tuesday, March 4th. They issued a “buy” rating and a $45.00 price target for the company.
About Sionna Therapeutics
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Featured Stories
- Five stocks we like better than Sionna Therapeutics
- What Does Downgrade Mean in Investing?
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Defense Stocks Set to Benefit From Increased Military Spending
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Aluminum Tariff Woes: Between 2 Stocks, 1 Shines Brighter
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
